AMRX vs CE · P/E 44, rev $2.79B vs rev $10.28B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Celanese Corporation (CE) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Celanese Corporation (CE) is a chemicals company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported CE revenue for 2024-12-31 was $10.28B. Net income was -$1.51B. Revenue was down 6.0% from 2023-12-31 to 2024-12-31. CE currently screens at market cap $5.92B.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. CE currently screens at market cap $5.92B.
Not investment advice. Open the AMRX and CE stock pages for the full models.
Not investment advice.